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Abstract
Background: Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in
southern China. The China 1992 TNM staging system has been widely used for prognosis
prediction of NPC patients in China. Although NPC patients can be classified according to their
clinical stage in this system, their prognosis may vary significantly.
Method: 280 cases of NPC with clinical follow-up data were collected and expressions of survivin
and VEGF in tumor tissues were investigated by immunohistochemistry (IHC). Apoptosis index
(AI) in 100 cases of NPC was detected by the TUNEL method.
Results: Expression of survivin and VEGF were significantly associated with TNM stage, T-stage
and metastasis of NPC. The patients with survivin and VEGF over-expression presented lower 5-
year survival rate, as compared to those of low-expression (42.32% vs. 70.54%, 40.1% vs. 67.8%,
respectively, P < 0.05), especially in advanced stage patients (36.51% vs. 73.41%, 35.03% vs. 65.22%,
respectively, P < 0.05). The 5-year survival rate in NPC patients with survivin and VEGF dual over-
expression was significantly lower than that of patients with dual low-expression (18.22% vs.
73.54%, respectively; P = 0.0003). Multivariate analysis indicated that both survivin and VEGF over-
expression in NPC tumor tissues were strong independent factors of poor prognosis in NPC
patients. The mean AI in the 39 survivin low-expression cases was 144.7 ± 39.9, which was
significantly higher than that in 61 survivin over-expression cases (111.6 ± 39.8) (T test, P < 0.05).
Conclusion: Survivin and VEGF over-expression are independent prognostic factors for the
patients with NPC. These results also suggest that tumor survivin and VEGF expressions are
valuable prognostic markers for prognosis prediction in NPC patients.
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Introduction
Inhibition of apoptosis may be involved in the pathogen-
esis of cancer by prolonging cell life and facilitating reten-
tion of deleterious mutations. Several inhibitors of
apoptosis related to the baculovirus inhibitors of apopto-
sis (IAP) gene have been identified[1]. Among these, a
structurally unique member of the IAP proteins, survivin,
a Mr~16.500 cytoplasmic protein with a single BIR and no
RING finger is unique for its expression in fetal tissue and
in a variety of human cancers, but not in non-proliferating
adult tissue[2,3]. In addition to its function as an inhibi-
tor of apoptosis, survivin is involved in the regulation of
cellular proliferation and angiogenesis in cancer [4,5].
Remarkably, increased survivin expression has been
observed in the most common human neoplasm, includ-
ing oesophageal cancer [6], ovarian carcinoma[7], laryn-
geal squamous cell carcinoma [8], colorectal carcinoma
[5], breast carcinoma[9] and lymphoma[10]. Most of
these studies have demonstrated a positive correlation
between survivin expression and poor prognosis of the
disease, where a multivariate statistical analysis has
revealed that survivin expression is an independent prog-
nostic factor for disease progression[6,10-12].
Angiogenesis is an essential step for tumor growth, play-
ing a critical role in tumor invasion and metastasis[13].
Tumors develop angiogenesis by secreting growth factors,
to stimulate endothelial migration and prolifera-
tion[14,15]. Among these growth factors, VEGF is
regarded as the main growth stimulatory factor in the
tumor-related angiogenesis[16]. Human VEGF is located
on chromosome 6p21.3 and it plays a critical role in the
initial phase of tumor growth and neo-vascularisa-
tion[17]. In vitro and in vivo experiments have shown
that increased VEGF expression is associated with tumor
growth and metastasis, whereas inhibition of VEGF
expression results in suppression of tumor growth and
tumor-induced angiogenesis [18]. Furthermore, A
number of studies in various cancer types have confirmed
that VEGF over-expression is closely correlated with the
presence of metastasis and recurrence and also with poor
survival rate of patients[14,19-22], including NPC.
NPC is one of the most common malignancies in certain
areas of southern China, South-Asia and North
Africa[23,24] and has a dominant clinicopathological
behavior of easily invasive and metastasis, which is differ-
ent from other head and neck cancers [25]. Metastasis to
regional lymph node or distant organ and local recurrence
are two major causes for treatment failure of this cancer.
Currently, the prediction of NPC prognosis is mainly
based on the clinical TNM staging, however, NPC patients
with the same clinical stage often present different clinical
outcomes, suggesting that the TNM stage is insufficient to
precisely predict the prognosis of this disease [26-29].
Therefore, it is important to search for novel molecular
biomarkers, which can help clinicians improve the prog-
nostic prediction and develop therapeutic intervention for
NPC patients. In this study, we assessed the expression of
survivin and VEGF in NPC and their correlations to the
clinicopathological parameters and overall survival of the
patients.
Materials and methods
Cases and clinical parameters
For this retrospective study, archival formalin-fixed, paraf-
fin-embedded specimens from 280 primary NPC patients
during 1992 ~ 2002 in Sun Yat-Sen University Cancer
Center (Guangzhou, China) were recruited. Tumors from
the paraffin blocks were underwent tissue microarray con-
struction before immunostaining. Paraffin sections were
directly dissected for pathological staining and immuno-
histochemistry. Tissue sections of NPC blocks were addi-
tionally dissected to single slide for apoptosis label in 100
cases of the NPC.
156 patients were diagnosed as differentiated non-kerati-
nized carcinoma (WHO type II) and 124 were diagnosed
as undifferentiated carcinoma (WHO type III). The
patients were 208 males and 72 females with age range
from 14 to 86 years (median age 46). The China NPC 92
staging system was used[30], patients were classified as 13
in stage I, 63 in stage II, 129 in stage III and 75 in stage IV.
All patients were treated with standard curative radiother-
apy with or without chemotherapy.
Tissue microarray construction
A fresh section stained with hematoxylin and eosin (HE)
was cut from each block. Individual donor blocks were
overlaid with the corresponding HE slides and the areas
for tissue microarray sampling were marked. Using instru-
mentation developed at the Mayo Clinic (Beech Instru-
ment Co., USA), two cylindrical cores of 1.0 mm in
greatest dimension were removed from each donor paraf-
fin block and transferred to premolded recipient paraffin
blocks at defined array positions. Recipient paraffin
blocks contained holes of appropriate dimension in a grid
pattern, maximally 11 holes wide by 14 holes in length,
allowing for 154 tissue cores per block. This construction
design permitted multiple blocks with identical array pat-
terns to be constructed simultaneously, serially sectioned
at 5 μm onto "charged" glass slides, and stored at 4°C.
Immunohistochemical staining and scoring
Polyclonal antibody aginst survivin at 1:200 dilution and
monoclonal antibody against VEGF in working solution
(Santa Cruz Inc., USA) were used in this study. Briefly, tis-
sue sections were de-waxed, incubated in retrieval buffer
solution for antigen recovery (DAKO Co., Denmark);
incubated with hydrogen peroxide for 10 minutes;Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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blocked with normal serum for 10 minutes; followed by
incubation with a primary antibody for 60 minutes and
detected by the Catalyzed Signal Amplification Kit (DAKO
Co, Carpinteria, USA). Visualization was developed with
diaminobenzidine (DAB). Negative controls were carried
out by substituting non-immune goat or rabbit serum for
the primary antibodies.
The immunostaining results were evaluated and scored
independently by two pathologists without knowledge of
the clinicopathological outcomes of the patients. Evalua-
tion of the immunostainning results was performed as
previously described[31]. Survivin staining results were
scored as four levels according to the percentage of cyto-
plasmic and/or nuclear specific positive tumor cells in 10
high power fields as follows. (-): less than 5%, (+):
5%–25%, (++): 25–50%, (+++): more than 50%. The sur-
vivin over-expression was defined as more than 25%
tumor cells with positive staining, whereas survivin low-
expression was less than 25%.
VEGF staining results were scored as four levels according
to the percentage of cytoplasmic and/or membrane posi-
tive cells in 10 high power fields as follow. (-): less than
10%, (+): 11%–20%, (++): 21–50%, (+++): more than
50%. The VEGF over-expression was defined as more than
10% tumor cells with positive staining, whereas VEGF
low-expression was less than 10%.
In situ detection of apoptosis and determination of 
apoptosis index (AI)
Apoptotic cells in 100 cases of NPC were identified by the
terminal-deoxynucleotidyl-transferase (TdT)-mediated
deoxyuridine triphosphate (dUTP) nick-end-labeling
(TUNEL) method (Boehringer Mannheim, Germany).
Methods and AI determination were according to previ-
ously described[32]. The AI was determined by micro-
scopic evaluation of apoptotic cells or apoptotic bodies in
100 high-power fields (100 × HPFs). The AI was equal to
the total number of apoptotic cells or bodies over total
number of tumor cells in 100 HPFs.
Statistical analysis
Data was analyzed using SPSS12.0 software. The associa-
tions between survivin, VEGF expression and clinico-
pathological parameters were assessed by Chi-Square test.
The correlation between survivin and VEGF was clarified
as Kappa Measure of Agreement test, and the relationship
between AI and survivin expression was analyzed by inde-
pendent samples t test. Kaplan-Meier analysis and log-
rank test were used to assess survival rate and to compare
the difference of survival rate. Univariate and multivariate
regression analyses were performed with the Cox propor-
tional hazards regression model to analyze the independ-
ent factors related to prognosis. P < 0.05 was considered
to be statistically significant.
Results
1. Association between survivin, VEGF expression and 
clinicopathological parameters in NPC
Immunostaining of survivin of the tissue array was repre-
sentative in Figure 1A. Cytoplasm and/or nucleic positiv-
ity for survivin staining were observed in tumor cells,
weak expression was observed in normal adjacent
nasopharyngeal epithelium (Figure 1B). Totally, 206 cases
of the NPC patients were adequate for the final analysis.
74 cases were excluded from this study because of inade-
quate survivin staining. Among the 206 cases, 44 (21.4%)
cases were negative (-), whereas 162 (78.6%) cases were
positive, of which, 54 cases (26.2%) were +, 70 cases
(34%) were ++, and 38 cases (18.4%) were +++. Over-
expression of survivin was observed in 108 (52.4%) out of
Immunohistochemistry and apoptosis staining of NPC tissue  microarray Figure 1
Immunohistochemistry and apoptosis staining of NPC tissue 
microarray. A. Positive staining of survivin shown under 
lower power field and B. Cytoplasm positive staining of sur-
vivin in the tumor cells and weak staining of the normal epi-
thelium of nasopharynx (arrow directed) C. Strong positive 
staining of VEGF in tumor cells; D. Cytoplasm positive stain-
ing of VEGF in the tumor cells and weak staining of the nor-
mal epithelium of nasopharynx (arrow directed); E. Weak 
staining of survivin in NPC tumor tissues; F. whereas several 
apoptotic bodies (arrow directed) were observed.Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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the 206 NPC tumor tissues, whereas low-expression was
observed in 98 cases (47.6%).
Expression of survivin was significantly associated with
the clinical stage (P = 0.018), T-stage (P = 0.004) and
lymph node metastasis (P = 0.028). No significant associ-
ation between survivin expression and age, gender, recur-
rence or distant metastasis was observed (Table 1).
VEGF positive staining was observed in both membrane
and cytoplasm of NPC tumor cells (Figure 1C), whereas
weak positive staining was observed in the normal epithe-
liums (Figure 1D). Totally, 188 cases of the NPC tumors
were adequate for the final analysis, 92 cases were
excluded from this study because of the VEGF inadequate
staining. Among the 188 tumor tissues, VEGF expression
was negative (-) in 102 cases (54.3%); whereas 86 cases
(45.7%) were positive, of which, 40 cases (21.3%) were +,
20 cases (10.6%) were ++, and 26 cases (13.8%) were +++.
VEGF over-expression was observed in 86 (45.7%) out of
the 188 cases, whereas VEGF low-expression was observed
in 102 cases (54.3%).
Expression of VEGF was significantly associated with clin-
ical stage, recurrence and distant metastasis (P < 0.05). No
correlation was observed between VEGF expression and
gender, age, T stage and lymph node metastasis (P > 0.05)
(Table 2). Furthermore, over-expression of survivin was
positively correlated with over-expression of VEGF in NPC
tumors (Kappa = 0.25) (Table 3).
2. Correlation between survivin expression and apoptosis 
in NPC
Total 100 NPC cases were conducted to in situ apoptosis
detection. The apoptotic cells and bodies appeared
labeled with an intense, dark blue reaction to easily distin-
guish the survivin low-expressed tumor cells (Figure 1E,
1F). The correlation between AI and survivin expression in
NPC was shown in Figure 2. Mean AI value was 128 ±
43.05 (95% CI, 119.6 ~136.7). Significant negative corre-
lation was observed between apoptosis and survivin
expression in NPC. The mean AI in the 39 survivin low-
expressed cases was 144.7 ± 39.9 (95% CI, 133.4~156.1),
which was significantly higher than that of the 61 tumors
with survivin highly expressed (111.6 ± 39.8; 95% CI,
100.2~122.9) (T test, P < 0.05).
3. Associations between survivin, VEGF expression, and 
survival of NPC patients
The 5-year survival rate and 10-year survival rate of the
cohort of the 280 NPC patients were 53.4% and 23.2%,
respectively (Figure 3A). The 5-year survival rate of the
Table 2: Relationship between VEGF expression and 
clinicopathological parameters of NPC patients
VEGF
Case High expression Low expression P value
(n = 188) (n = 86) (n = 102)
Age (years)
<46 95 41 54 0.472
≥46 93 45 48
Sex
Male 147 67 80 0.931
Female 41 19 22
Histological 
type (WHO)
II 124 55 69 0.253
III 64 31 33
T stage
T1~2 71 27 44 0.098
T3~4 117 59 58
N stage
N0 48 23 25 0.726
N1~3 140 63 77
TNM stage
I/II 42 13 29 0.029
III/IV 146 73 73
Recurrence
Yes 58 36 22 0.004
No 130 50 80
Metastasis
Yes 23 16 7 0.024
No 165 70 95
Table 1: Correlations between survivin expression and 
clinicopathological parameters of NPC patients
Survivin
Case High expression Low expression P value
(n = 206) (n = 108) (n = 98)
Age
<46 95 53 42 0.371
≥46 111 55 56
Sex
Male 152 75 77 0.137
Female 54 33 21
Histological 
type (WHO)
II 138 76 62 0.283
III 68 32 36
T stage
T1~2 82 33 49 0.004
T3~4 124 75 49
N stage
N0 49 19 30 0.028
N1~3 157 89 68
TNM stage
I/II 48 18 30 0.018
III/IV 158 90 68
Recurrence
Yes 47 27 20 0.433
No 159 81 78
Metastasis
Yes 24 13 11 0.856
No 182 95 87Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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280 patients with clinical stage I/II and stage III/IV were
72.6% and 49.6%, respectively. There was a statistical sig-
nificance (P  = 0.0094) (Figure 3B). When the patient
cohort was stratified according to gender, the 5-year sur-
vival rate of male patients was significantly lower than
that of female patients (47.9% vs. 78.7% respectively, P =
0.0004) (Figure 3C). Further analysis revealed that in this
group of NPC patients, female patients were more likely
to have an earlier stage compared with male patients
(37.5% vs. 23.6%). So the favorable prognosis in female
patients may be due to the earlier stage in these NPC
patients (data is not shown).
According to expression of survivin, the 5-year survival
rate of the NPC patients with survivin over-expression was
42.32% (n = 108), which was significantly lower than that
in NPC patients with survivin low-expression (70.54%, n
= 98, P  = 0.0006; Figure 4A). Furthermore, when the
patient cohort was divided depending on clinical stage
and stratified according to tumor expression of survivin,
in patients with advanced clinical stage (stages III+IV), the
5-year survival rate of patients with survivin over-expres-
sion was significantly lower than that of patients with sur-
vivin low-expression (36.51% vs. 73.41%, respectively; P
= 0.0002; Figure 4C); whereas in the patients with early
stage (stages I+II), the difference between survivin over-
expression and survivin low-expression was not signifi-
cant (64.22% vs. 80.46%, respectively; P = 0.7136; Figure
4B).
When the patient cohort was stratified according to VEGF
expression in the tumor cells, the 5-year survival rate of
the NPC patients with VEGF over-expression was 40.1%
(n = 86), which was significantly lower than that of NPC
patients with VEGF low-expression (67.8%, n = 102, P =
0.0028; Figure 5A). Furthermore, when the patient cohort
was divided by clinical stages and stratified according to
expression of VEGF, in NPC patients with advanced clini-
cal stage (stages III+IV), the 5-year survival rate in NPC
patients with VEGF over-expression was significantly
lower than that of patients with VEGF low-expression
(35.03% vs. 65.22%, respectively; P = 0.0025; Figure 5C);
whereas in early stages NPC (stages I+II), the difference
was not significant between NPC patients with VEGF over-
expression and those with VEGF low-expression (60.46%
vs. 73.17%, respectively; P = 0.554; Figure 5B).
When the patient cohort was stratified according to tumor
expression of both VEGF and survivin in 175 patients, The
5-year survival rate in 48 NPC patients with survivin and
VEGF dual over-expression was significantly lower than
that of 62 patients with dual low-expression (18.22% vs.
73.54%, respectively; P = 0.0003; Figure 5D).
Using multivariate regression analysis of the entire group
of patients, male patients (P = 0.026), distant metastasis
(P  = 0.002), VEGF over-expression (P  = 0.005) and
suvivin over-expression (P  = 0.031) were significantly
associated with poor overall survival (Table 4). In addi-
tion, each of these four variables was identified as prog-
nostically significant by univariate analysis (Table 5),
which demonstrated that the four variables were all inde-
pendent predictors for the overall survival.
Discussion
Multiple genetic pathways control apoptosis, and parts of
them may be regulated by survivin gene, but potential
mechanism of apoptosis in NPC has not been identified.
In this study, we found that the expression of survivin pro-
tein in NPC tumor tissues was positively correlated with
progression of the patients, especially with primary tumor
invasion. Over-expression of survivin may not only play
some roles in NPC pathogenesis but also in NPC progres-
sion.
Correlation between survivin expression and apoptosis in  NPC, The mean AI in the survivin low-expression cases was  significantly higher than that of in survivin over-expression  cases (P < 0.05) Figure 2
Correlation between survivin expression and apoptosis in 
NPC, The mean AI in the survivin low-expression cases was 
significantly higher than that of in survivin over-expression 
cases (P < 0.05).
Table 3: Correlations between survivin and VEGF expression in 
NPC   tissues
VEGF
High expression Low expression Kappa value
Survivin
High expression 48 (56.5%) 37 (43.5%) 0.25
Low expression 28 (31.1%) 62 (68.9%)Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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In the present study, positive survivin staining was
detected in 78.6% (162/206) of NPC cases, with a variable
proportion of positive tumor cells. We also identified that
survivin over-expression was a significant independent
predictor of overall survival (P = 0.0006). As mentioned
above, survivin expression was previously reported to sig-
nificantly correlate with poor prognosis in a range of
malignant tumors, such as colorectal cancer [12], bladder
cancers [33], lymphoma[10], soft-tissue sarcomas[11].
However, so far, there were only few reports about the cor-
relation between survivin expression in NPC and its prog-
nosis. Over-expression of survivin in NPC tumor was
reported to be positively correlated with poor prognosis of
the patients [34,35]. Our results showed that the 5-year
A, Kaplan-Maplan curves for overall survival rates of 280 patients with NPC Figure 3
A, Kaplan-Maplan curves for overall survival rates of 280 patients with NPC. B, Kaplan-Maplan curves for overall survival rates 
of different clinical stage, patients with stage III/IV have a lower survival rate than those with stage I/II (P = 0.0094, log rank 
test). C, Kaplan-Maplan curves for overall survival rates of female and male paitents, male patients present lower survival rate 
than female paitents (P = 0.0004, log rank test)Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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survival rate of the NPC patients with survivin over-
expression was significantly lower than that of NPC
patients with survivin low-expression, especially in
advanced clinical stage (stages III and IV) NPC patients.
Our large cases study was a powerful proof for previous
conclusion that detection of survivin protein expression
in the tumor tissue was helpful for predicting prognosis of
NPC patients. Moreover, our results also showed over-
expression of survivin was a specific poor prognostic fac-
tor for advanced stage NPC patients.
VEGF is considered to be the most cardinal vascular
growth factor prompting tumor angiogenesis. Accumulat-
ing studies so far suggest that over-expression of VEGF has
A, Kaplan-Meier curve showing the patients with survivin over-expression have a lower suvivial rate than those with survivin  low-expression (P = 0.0006) Figure 4
A, Kaplan-Meier curve showing the patients with survivin over-expression have a lower suvivial rate than those with survivin 
low-expression (P = 0.0006). B, no significant difference of 5-year survival rate was found between survivin over-expression 
and low-expression in NPC patients with early stage (stage I/II, P = 0.7136). C, significant difference of 5-year survival rate was 
found between survivin over-expression and low-expression in NPC patients with advanced stage (stage III/IV, P = 0.0002)Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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an positive influence on tumor growth, metastatic poten-
tial, failure to radiotherapy and poor prognosis[21,36-
40]. In head and neck squamous cell carcinomas, VEGF is
a marker of tumor invasion and metastasis [41]. In NPC,
the level of serum-VEGF has been reported to be signifi-
cantly elevated in the patients, which was correlated with
primary tumor progression, local recurrence or distant
metastasis, and poor prognosis[42,43]. In this large sam-
ple study, we found that VEGF over-expression in NPC
tumor was significantly correlated with advanced clinical
stage, local recurrence and distant metastasis of the dis-
ease, and poor prognosis of the patients, which was in
A, Kaplan-Meier curve showing the patients with VEGF over-expression have lower 5-year survival rate than those with VEGF  low-expression (P = 0.0028) Figure 5
A, Kaplan-Meier curve showing the patients with VEGF over-expression have lower 5-year survival rate than those with VEGF 
low-expression (P = 0.0028). B, Among the patients of stage I/II, no significant difference of 5-year survival rate was found 
between patients with VEGF over-expression and low-expression (P = 0.554). C, Among the patients of stage III/IV, VEGF 
over-expression group presents lower 5-year survival rate than the VEGF low-expression group (P = 0.0025). D, The patients 
with dual survivin and VEGF over-expression have significant lower 5-year suvivial rate than those with dual survivin and VEGF 
low-expression group (P = 0.0003), and those with non-dual expression group (P = 0.001)Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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accordance with previous reports in NPC and other malig-
nancies [14,21,38-40,44]. Further survival analysis
revealed that over-expression of VEGF in the NPC tumor
tissue was significantly correlated with decreased 5-year
survival rate, especially in patients with advanced clinical
stage (stages III and IV), the 5-year survival rate in patients
with VEGF over-expression was significantly worse than
that of patients with VEGF low-expression. This finding
agreed with the results of previous studies that increased
tumor VEGF expression was related to poor prognosis of
NPC patients [45-47]. These results suggest that VEGF
may play an important role in local recurrence and metas-
tasis through induction of angiogenesis in NPC, and
VEGF expression is a valuable prognostic marker for prog-
nosis prediction in advanced stage NPC patients.
Furthermore, we found that over-expression of survivin
was significantly positively correlated with over-expres-
sion of VEGF in NPC. Importantly, the patients with dual
over-expression of both survivin and VEGF presented a
worse prognosis than those with dual low-expression. The
5-year survival rate of NPC patients with survivin and
VEGF dual over-expression was significantly lower than
that of patients with dual low-expression. Multivariate
analysis indicated that both survivin and VEGF expression
in NPC tumor tissues were strong independent factors for
poor prognosis of NPC patients (Table 5). These results
indicated that co-analysis of VEGF and survivin protein
expression in NPC tumor tissues was more valuable for
prognosis evaluation of NPC patients.
To our knowledge, the present data firstly provide a com-
pelling case confirming a correlation among the survivin
expression, VEGF expression and the survival of NPC
patients. As EBV infection was one of the important etiol-
ogy factors of NPC, and EBV encoded oncoprotein LMP1
was frequently detected in NPC tumor tissues[32], several
studies reported that in NPC carcinogenesis, LMP1 up-reg-
ulate survivin and VEGF expression directly or indirectly
[48-50]. Previous studies also reported that survivin as
one of the target genes induced by VEGF in endothelium,
which was associated with prominent up-regulation of
survivin in newly formed blood vessels during angiogen-
esis in vivo [51]. Taking together, we assume that in NPC,
LMP1 induction of over-expression of suvivin and VEGF,
enhance tumor angiogenesis tumor cell infiltration and
invasion, and inhibit apoptosis of tumor cells, result in
poor prognosis. However, further investigation about this
is needed.
Conclusion
Currently, clinical TNM stage is insufficient to predict the
NPC prognosis, patients of the same clinical stage often
show different clinical course. This study demonstrates
that expression of survivin is consistent with expression of
VEGF in NPC and both are closely correlated with poor
prognosis of NPC. We suggest that detection of survivin
and VEGF expression might aid in the stratification of
patients with NPC, especially divided advanced stage NPC
into two separate groups whose prognosis was signifi-
cantly different. In advanced stage NPC patients, Survivin
and VEGF high expression render tumor cell resistant to
the conventional therapies including radiotherapy and/or
chemotherapy and may need more systemic treatment or
targeted antagonists of survivin and VEGF therapy.
List of abbreviations
NPC, nasopharyngeal carcinoma; 
EBV, Epstein-Barr virus; 
VEGF, vascular endothelial growth factor; 
AI, apoptosis index; 
IAP, inhibitors of apoptosis.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Table 5: Univariate Analysis of Cox Proportional Hazards Model 
for Overall Survival in NPC patients
Characteristics Hazard ratio 95%CI P
Age (years, <46 vs. ≥ 46) 1.558 1.044–2.326 0.030
Sex (male vs. female) 0.447 0.264–0.754 0.003
T-stage (T1~2 vs. T3~4) 1.386 0.914–2.101 0.124
N-stage (N0 vs. N1~3) 0.978 0.628–1.524 0.923
Clinical stage (I/II vs. III/IV) 1.817 1.091–3.025 0.022
Recurrence (no vs. yes) 1.560 1.018–2.391 0.041
Metastasis (no vs. yes) 2.023 1.177–3.478 0.011
VEGF (low expression vs. 
over-expression)
2.112 1.277–3.495 0.004
Survivin (low expression vs. 
over-expression)
2.132 1.301–3.494 0.003
Table 4: Multivariate Analysis of Cox Proportional Hazards 
Model for Overall Survival in NPC patients
Characteristics Hazard ratio 95%CI P
Sex (male vs. female) 0.463 0.235–0.911 0.026
VEGF (low expression vs. 
over-expression)
2.205 1.266–3.839 0.005
Survivin (low expression vs. 
over-expression)
1.834 1.056–3.184 0.031
Metastasis (no vs. yes) 3.598 1.614–8.021 0.002Journal of Translational Medicine 2008, 6:1 http://www.translational-medicine.com/content/6/1/1
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